Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5868-5873

  Sobrero, Alberto ^a   Bruzzi, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; GEMCITABINE; LAPATINIB; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NOTE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAMPLE SIZE; SOLID TUMOR; TREATMENT DURATION; ARTICLE; BIOASSAY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; ECONOMICS; METHODOLOGY; MORTALITY; NEOPLASM; PHASE 3 CLINICAL TRIAL; RISK ASSESSMENT; STANDARD; SURVIVAL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUG COSTS; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73349122015     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.4162     Document Type: Note

References (38)

1. Rothenberg ML, Carbone DP, Johnson DH: Improving the evaluation of new cancer treatments: Challenges and opportunities. Nat Rev Cancer 3:303-309, 2003
2. Carney DN: Lung cancer-time to move on from chemotherapy. N Engl J Med 346:126-128, 2002
3. Roberts TG Jr, Lynch TJ Jr, Chabner BA: The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision. J Clin Oncol 21:3683-3695, 2003
4. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
5. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
6. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus Interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
7. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alpha 2a for treatment of metastatic renal cell carcinoma: A randomised doubleblind plase III trial. Lancet 370:2103-2111, 2007
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
9. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
10. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
11. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
12. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 353:123-132, 2005
14. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
15. Demetri GD, van Oosterom AT, Garrett CR: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
16. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
17. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
18. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma: SHARP Investigators Study Group. N Engl J Med 359:378-390, 2008
19. Van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
20. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
21. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
22. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003
23. Schilsky RL: End points in cancer clinical trials and the drug approval process. Clin Cancer Res 8:935-938, 2002
24. Dancey JE, Freidlin B: Targeting epidermal growth factor receptor-are we missing the mark? Lancet 362:62-64, 2003
25. Roberts TG Jr, Chabner BA: Beyond fast track for drug approvals. N Engl J Med 351:501-505, 2004
26. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
27. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
28. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
29. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
30. Sobrero A, Kerr D, Glimelius B, et al: New directions in the treatment of colorectal cancer: A look to the future. Eur J Cancer 36:559-566, 2000
31. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer-a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
32. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
33. Vervenne W, Bennouna J, Humblet Y, et al: A randomized double blind placebo controlled trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 26:214s, 2008 (abstr 4507)
34. Spiegelhalter DJ, Freedman LS, Parmar MK: Applying Bayesian ideas in drug development and clinical trials. Stat Med 12:1501-1511, 1993
35. Parmar MK, Griffiths GO, Spiegelhalter DJ, et al: Monitoring of large randomised clinical trials: A new approach with Bayesian methods-CHART steering committee. Lancet 358:375-381, 2001
36. Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 23:3456-3461, 2007
37. Ychou M, Raoul JL, Douillard JY, et al: A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674-680, 2009
38. Lachin JM: A review of methods for futility stopping based on conditional power. Stat Med 24:2747-2764, 2005